Search clinical trials for: safety tolerability and immunogenicity of two different doses of DLX105 applied intra-dermally into

Total 493387 results

Genentech, Inc.

Active, not recruiting

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Advanced/Metastatic Tumors

Spain, United States, Korea, Republic of, Australia, France, Japan, Canada
Novartis Vaccines

Completed

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

Influenza

Finland, United States, Poland
Pfizer

Completed

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women

Group B Streptococcus Infections

United States
Dynavax Technologies Corporation
United States Department of Defense

Completed

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Vaccine-Preventable Diseases | Plague | Plague, Pneumonic

United States
argenx

Completed

IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers

Healthy Volunteers
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Pneumococcal Infections

United States
Novartis Pharmaceuticals

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

Progressive Supranuclear Palsy (PSP)

Germany, United Kingdom, Canada, United States
GlaxoSmithKline

Completed

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Malaria

Ghana, Kenya
Universidad Católica San Antonio de Murcia

Completed

Blood Bioavailability of Two Different Doses of a β-alanine Supplement (BIo-β) (Bio-β)

Bioavailability

Spain
National Cancer Institute (NCI)

Suspended

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
VBI Vaccines Inc.

Completed

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a

Covid19

Canada
AstraZeneca

Completed

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

Idiopathic Pulmonary Fibrosis

United States
Seqirus
Biomedical Advanced Research and Development Authority

Active, not recruiting

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

Infections | Virus Diseases | Respiratory Tract Infections | Influenza, Human | Infection Viral

United States
University of Oxford
Malaria Research and Training Center, Bamako, Mali

Active, not recruiting

Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Malaria

Mali, United Kingdom
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP

Malaria

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Influenza Immunization

Australia, United States, Puerto Rico
Madrigal Pharmaceuticals, Inc.

Enrolling by invitation

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

Renal Impairment

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

Pneumonia, Pneumococcal

United States, Canada, France, Israel, Italy, Japan, Korea, Republic of, Spain, Taiwan
IrsiCaixa
José Moltó Marhuenda, PhD, MD; Beatriz Mothe Pujadas PhD,MD; Susana Benet Garrabé... and other collaborators

Completed

A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals

HIV Infection

Spain
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants

Healthy Participants

Germany
UCB Biopharma SRL

Active, not recruiting

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis (BE CONNECTED)

Moderate to Severe Plaque Psoriasis

United States, Canada, Germany, Poland
GlaxoSmithKline

Terminated

A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants

Heart Failure

United Kingdom
Ra Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE)

Myasthenia Gravis, Generalized

United States, Canada, France, Germany, Italy, Japan, Norway, Poland, Spain, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Depressive Disorder, Treatment-Resistant

United States, China
National Institute of Allergy and Infectious Diseases...
Moderna TX, Inc

Active, not recruiting

Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults

Nipah Virus Infection

United States
Kyowa Kirin Co., Ltd.

Terminated

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)

Acute Myelogenous Leukemia (AML)

United States
ModernaTX, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

Cytomegalovirus Infection

United States, Australia, Canada, France, Belgium, Germany, Israel, Italy, United Kingdom, Spain, Estonia, Finland, Japan
Celgene

Active, not recruiting

A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer

Small Cell Lung Carcinoma

France, Italy, Spain
Chinook Therapeutics, Inc.

Active, not recruiting

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

IgA Nephropathy

Korea, Republic of, United States, United Kingdom
Dompé Farmaceutici S.p.A
Cross Research S.A.

Completed

Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye

Dry Eye Syndrome

Austria
GlaxoSmithKline

Completed

A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Multiple Myeloma

China
Vaxcyte, Inc.

Completed

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

Pneumococcal Vaccines

United States
Shanghai Henlius Biotech

Active, not recruiting

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects

Multiple Myeloma

China
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration (FALCON)

Age-related Macular Degeneration

Germany, Switzerland
Ascendis Pharma Growth Disorders A/S

Enrolling by invitation

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia (AttaCH)

Achondroplasia

United States, Australia, Denmark, Ireland, Austria, Germany, New Zealand
Vaxcyte, Inc.

Completed

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults

Pneumococcal Vaccines

United States
TJ Biopharma Co., Ltd.

Withdrawn

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

First-line Non-small-cell Lung Cancer | First-line Urothelial Carcinoma | Second-line Urothelial Carcinoma | Second-line Melanoma

China
TJ Biopharma Co., Ltd.

Terminated

A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)

China
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older

Herpes Zoster

Germany, Czechia, Sweden
Nykode Therapeutics ASA
Vaccibody AS

Completed

A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers

Infections | COVID-19 | Infection Viral

Norway
Emergent BioSolutions

Completed

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Typhoid

United States
Pfizer

Completed

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease (MONET)

RESPIRATORY SYNCYTIAL VIRUS (RSV)

United States
Taizhou Mabtech Pharmaceutical Co.,Ltd

Terminated

Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC

Squamous Cell Carcinoma of the Head and Neck

China
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above

Respiratory Syncytial Virus Infections

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Influenza Immunization

Puerto Rico, United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

Spain, United States, Italy, United Kingdom, Hungary, France, Poland, Australia, Bulgaria, Czechia, South Africa
OncoC4, Inc.

Withdrawn

Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841

Advanced Solid Tumor
Pfizer

Completed

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

Ovarian Cancer | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck

United States, Spain
Seqirus

Completed

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

Influenza, Human

United States
Matrivax Research and Development Corporation

Active, not recruiting

A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine

Pneumococcal Vaccine

United States

3

Subscribe